Wang Highlights Treatment Options after Resistance to Cellular Therapies in MCL

January 28, 2020
Michael Wang, MD

Michael Wang, MD, discusses the approaches physicians can use when treating their patients with mantle cell lymphoma who have become resistant to cellular therapies, such as CAR T-cell therapy.

Michael Wang, MD, a professor in the Department of Lymphoma and Myeloma at The University of Texas MD Anderson Cancer Center, discusses the approaches physicians can use when treating their patients with mantle cell lymphoma (MCL) who have become resistant to cellular therapies, such as chimeric antigen receptor (CAR) T-cell therapy.

According to Wang, there are numerous options available now, including precision medicine and targeted therapies. Physicians can target, sequence, and biologically study a patient with MCL to decide what the key driver is that is causing resistance to cellular therapy. With this approach, physicians can attack the Achilles heel of each patient’s particular resistance mechanisms of the disease.

Following cellular therapy, precision medicine can be used in the future depending on the biology of the disease. Wang says there has never been a better time to be a doctor in the field of MCL, and he shares that it is his dream to cure as many patients with MCL as possible.

<< View more resources and information regarding mantle cell lymphoma